[In vitro activity of telithromycin against community acquired respiratory pathogens].

Autor:	Ulloa F MT; Programa de Microbiología y Micología, Facultad de Medicina, Universidad de Chile, Independencia 1027, Clasificador 7, Independencia, Santiago, Chile. mtulloa@med.uchile.cl, Camponovo C R, Fernández V A, García C P, Prado J V, González A P, Rojas S P, Inostroza S J, Lafourcade R M, Aguilera A L, Porte T L, Cruz P C, Joyas M A, Alcaide L B, Pinto C ME, Giglio M MS
Jazyk:	Spanish; Castilian
Zdroj:	Revista medica de Chile [Rev Med Chil] 2005 Apr; Vol. 133 (4), pp. 419-25. Date of Electronic Publication: 2005 Jun 08.
DOI:	10.4067/s0034-98872005000400004
Abstrakt:	Background: Telithromycin is a new ketolide antimicrobial, that can be useful for the treatment of respiratory infections. Aim: To compare in vitro activity of telithromycin against respiratory pathogens, isolated in outpatient clinics. Material and Methods: Two hundred eighty strains isolated from patients with respiratory infections, were studied. The strains studied were S pneumoniae, penicillin sensitive (SPNS:57); intermediate (SPNI:35), resistant (SPNR:25); S pyogenes (SP:57); H influenzae (HIN 51); M catarrhalis (MC:25) and S aureus meticillin sensitive (SAUS:30). Minimal inhibitory concentration (MIC) by broth microdilution was studied for telitrhomycin and levofloxacin in all strains. Other antimicrobials studied, but not in all strains were erythromycin, clindamycin, trimetoprim sulphamethoxazole, oxacillin, amoxicillin-clavulanic acid and cefuroxime. Results: All strains were sensible to telithromycin at a concentration -4 microg/ml. MIC 90 and its range for SPNS was 0.03 microg/ml (-0.004-0.12), for SPNI was 0.03 microg/ml (-0.004-025), for SPNR was 0.06 microg/ml (-0.004-0.25), for HIN was 2 microg/ml (0.12-4), for SP was 0.5 microg/ml (-0.004-2), for MC was 0.5 microg/ml (0.06-2) and for SAU was 0.25 microg/ml (0.06-0.25). Conclusions: All studied pathogens were sensible to telithromycin in vitro. This antimicrobial is an alternative for the treatment of community acquired respiratory infections.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu